Jola Mehmeti, PharmD, MBA

home / authors / jola-mehmeti-pharmd-mba

Jola Mehmeti is a 2018 PharmD graduate from the UConn School of Pharmacy. She is a PGY1 Clinical Research Pharmacy Resident at Michigan Medicine. Connect with her on LinkedIn or send a message to contact@jolamehmeti.com.

Articles

Site Logo

A Quick Overview of CDK4/6 Inhibitor Palbociclib

Jola Mehmeti, PharmD, MBA
July 12th 2018

Approvals and indications of this drug were based on 3 main clinical trials.

Read More

Site Logo

Answers to Common Questions About Studying for the MPJE

Jola Mehmeti, PharmD, MBA
July 4th 2018

Studying for the MPJE can be daunting. Numerous online threads offer advice on where to start

Read More

Site Logo

Five Food Allergens Pharmacists Should Know

Jola Mehmeti, PharmD, MBA
June 27th 2018

Food allergens can be present in a variety of medications, but they don't always merit a switch in therapy.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD